IMMP:NASDAQ
Immutep Ltd - ADR
0,57 US$
arrow_upward
+0,37%(+0,0021) 1 d
0,58 US$
arrow_upward
+1,22% (+0,0070)bedtimeEfter stängning
Stängd: 24 apr., 16:00:00 GMT−4 · USD
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för IMMP …
Öppen
0,56 US$
Högt
0,58 US$
Lågt
0,56 US$
Börsvärde
73,53 mn
Genomsn. vol.
28,73 mn
Volym
1,89 mn
52v högst
3,53 US$
52v lägst
0,29 US$
EPS
−0,41 US$
Beta
2,20
Utestående aktier
147,37 mn
Antal anställda
19
Nyheter och artiklar
Från källor på webben
PR Newswire
·
för 22 timmar sedan
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Meyka
·
för 2 dagar sedan
IMM.AX Stock Surges 1.37% on ASCO Presentation News, 24 Apr 2026
Profil
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
Om Immutep Ltd - ADR
AI-innehåll kan innehålla fel. Läs mer